\documentclass{article}

\usepackage{amsmath}
\usepackage{graphicx} % usage e.g. \includegraphics[width=12cm]{results.eps}

\usepackage{color}
\definecolor{light-gray}{gray}{0.95}
%\usepackage{hyperref}
\usepackage{listings}

\def \blhc {spnhyh} %bottom left hand corner
\input{margins.ltx}

% added in this document
\usepackage{hhline}
\usepackage{float}

%paragraph spacing and indenting
\setlength{\parindent}{0em}
\setlength{\parskip}{1em}
\renewcommand{\baselinestretch}{1.5}


\begin{document}
\title{Spinoff: Halyard Health case study}
\author{Mark Carter}
\maketitle

\begin{abstract}
This article provides a case study for KMB's (Kimberley Clark) spinoff of HYH (Halyard Health) \cite{about} announced late September, 2014.
\end{abstract}

\section{Background to the spinoff}


27-Sep-2014: KMB announced that they would spin off HYH at around the end of October 2014. External funding would consist of Senior secured term loan B \$390m, senior unsecured notes \$250m, senior secured revolving credit facility \$250. The last item would be expected to be undrawn.

12-Oct-2014: KMB announced that shareholders would receiver 1 HYH share for 8 KMB shares, with trading starting 3 November. HYH would be expected to generate sales of about \$1.6n pa, and have 16,000 employees.

14-Oct-2014: SeekingAlpha estimated it would have a market cap of \$6b.

25-Oct-2014: KMB has a market cap of \$41.7b, with sales of \$31.2b. HYH would have a small market cap in relation to KMB, which is generally considered a plus in spinoff situation.  HYH operates in the ares of Surgical and infection preventation, and medical devices. KMB will receive a one-time payment from HYH.

The 10-K \cite{k10}, filed on 6 May 2014, with significant information given in the tables below.

\begin{table}[h]
\centering
\caption{Extracts from the P\&L account, from page 42 of the 10-K}
\begin{tabular}{lr}
 &  \$m  \\
Net Sales & 1677.5  \\
Operating Profit & 225.2  \\
Income before taxes &  227.8 \\ 
Taxes & -73.2 \\
Net Income & 154.6
\end{tabular}
\end{table}


%\begin{figure}
\begin{table}[h]
\centering
\caption{Extracts from Balanace Sheet, from page 43 of the 10-K}
\begin{tabular}{lrr}
 &  \$m  & \$m \\
Fixed assets & & 1898.9 \\
Current assets & 585.1 & \\
Current Liabilities & 310.4  & \\ \cline{2-2}
Net current assets & 274.7 & 274.7 \\
Long-term liabilities & & -94.5 \\ \cline{3-3}
Equity & & 2079.1  \\\hhline{~~=} 
\end{tabular}
\end{table}
%\end{figure}

28-Oct-2014 The company noted that ``The spin-off will ket Halyard Health purse its own value-creation opportunities as a focussed healthcare company''.

Comparison with companies is given in table \ref{tbl:compare}, which shows that that HYH is the cheapest, assuming a share price of \$37.97.

\begin{table}[H]
\centering
\caption{Comparison of HYH with other companies. Assumes a share price of \$37.97}
\label{tbl:compare}
\begin{tabular}{lrrrrr}
 & MKT & REV&  OP & MKT/ & MKT/ \\
 & \$m & \$m & \$m & REV & OP \\

HRC & 2535.73 & 1716.2 & 154.90 & 1.478 & 16.37 \\
SYK & 32929.02 & 9021.0 & 1256.00 & 3.650 & 26.22 \\
ZMH & 1849.24 & 4623.40 & 1035.60 & 3.993 & 17.82 \\
CNMD & 1157.22 & 762.70 & 56.24 & 1.517 & 20.58 \\
SNN  & 15077.08 & 4351.00 & 810.00 & 3.465 & 18.61 \\
GMED & 1972.27 & 434.46 & 101.67 & 4.540 & 19.40 \\
\textbf{MEAN} & & & & \textbf{3.558} & \textbf{19.83} \\
\\
HYH & 1755.91 & 1677.50 & 225.3 & 1.047 & 7.79 \\ 
\end{tabular}
\end{table}


01-Nov-2014: There is an announcement that KMB is being sued for \$500m over gown Ebola protection claims. The gowns are made by Kimberley Clark Health Care, a division that is being spun off


\section{Initial trading}

03-Nov-2014: HYH begins trading on the NYSE.

03-Nov-2014: \emph{The Star Online}: ``HYH IPO set to shine. Since Ebola was first diagnosed in the US, demand has surged for the eye shields, face masks and disposable gowns made by HYH''.

04-Nov-2014: \emph{Fox Business}: HYH ``makes muted market debut''.

15-Nov-2014 \emph{Seeking Alpha}: ``At a price of \$38, the company is valued at \$1.77b, based on 46.5m shares outstanding. HYH's P/E=14.09, a modest discount to peer C.R. Bard (BCT). No immediate plans for dividends''

18-Nov-2014: I bought some shares at \$38.34. 

A plot of the share price and volume for the pre-market, and subsequent initial trading, is shown below.
\begin{figure}[H]
\includegraphics[width=12cm]{hyh-01.eps}
\end{figure}

\input{bibli.ltx}
\end{document}
